Improved Vδ2+ T cells recovery correlates to reduced incidences of mortality and relapse in acute myeloid leukemia after hematopoietic transplantation.
|
| Abstract |
Acute myeloid leukemia (AML) patients can benefit from allogeneic hematopoietic cell transplantation (alloHCT) and achieve long-term remission. Recovery of T cell quantity and quality is critical to reduce the incidences of life-threatening complications after alloHCT. Although the general recovery level of γδ T cells is recognized to be associated with outcomes of patients who suffered from various hematological diseases and received alloHCT, the correlation between γδ T cell subsets and the prognosis in AML patients following transplantation remains to be investigated. In the current study, the recoveries of T cell subpopulations in 103 AML patients were dissected at different time points after haploidentical HCT (haploHCT). Statistical analyses showed that the absolute number of Vδ2+ T cells on day 90 was an independent risk factor for predicting 2-year OS in AML patients following haploHCT. The survival advantage from the improved recovery of day-90 Vδ2+ T cells was attributed to reducing the infection-related mortality. Consistently, lower 2-year non-relapse mortality was found in recipients with higher day-90 levels of Vδ2+ T cells. Notably, day-270 Vδ2+ T cell numbers reversely correlated to both 2-year and 5-year probabilities of relapse in this scenario. These results highlighted the significant correlation of Vδ2+ T cells recovery with long-term survival and relapse after alloHCT, suggesting that Vδ2+ T cells-based immune strategies may help control infectious complications and leukemia recurrence in AML patients.
|
|---|---|
| Authors | Keli Yue, Haitao Gao, Shuang Liang, Ning Wu, Cong Cheng, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Yifei Cheng, Xiao-Jun Huang, Jiangying Liu |
| Journal | Annals of hematology (Ann Hematol) Vol. 102 Issue 4 Pg. 937-946 (Apr 2023) ISSN: 1432-0584 [Electronic] Germany |
| PMID | 36763109 (Publication Type: Journal Article) |
| Copyright | © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!